Market Overview

Insys Therapeutics Shares Fall Following Publication Of Cleveland Research Report

Share:
Related INSY
Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression
Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids
Cannabis Stock Survey - Public (Marketfy Insights)

Shares of Insys Therapeutics (NASDAQ: INSY) dropped 10 percent Thursday.

The company experienced selling pressure as news hit that Cleveland Research showed that both Express Scripts and CVS will be reviewing new drug debuts on a quarterly basis.

The research report noted that Insys' Subsys product could be excluded from sale if it doesn't add either clinical or financial value. Cleveland Research commented further saying formulary changes suggest ESRX will block Vertex's Incivek in favor of J&J/Medivir. ESRX may look to exclude Gilead's Sovaldi or other competing products in Hepatitis C once new drugs reach the market later this year.

Shares of Insys Therapeutics closed at $27.03, down 10.14 percent.

Posted-In: Cleveland ResearchNews Health Care FDA General

 

Related Articles (INSY)

View Comments and Join the Discussion!